Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Marketed
Current status date:
2010-06-06
Original market date: See footnote 1
2010-06-06
Product name:
BI-PEGLYTE
DIN:
02326302
Product Monograph/Veterinary Labelling:
Date:
2021-03-25
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
PENDOPHARM DIVISION OF PHARMASCIENCE INC
100
6111 Royalmount Ave
Montreal
Quebec
Canada
H4P 2T4
Class:
Human
Dosage form(s):
Tablet (Delayed-Release) , Powder For Solution , Kit
Route(s) of administration:
Oral
Number of active ingredient(s):
6
Schedule(s):
Ethical
American Hospital Formulary Service (AHFS): See footnote 3
56:12.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
A06AB52 BISACODYL, COMBINATIONS
Active ingredient group (AIG) number:See footnote5
0652579001
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| BISACODYL | 5 MG / TAB |
| POLYETHYLENE GLYCOL 3350 | 59.55 G / SACHET |
| POTASSIUM CHLORIDE | 0.76 G / SACHET |
| SODIUM BICARBONATE | 1.69 G / SACHET |
| SODIUM CHLORIDE | 1.46 G / SACHET |
| SODIUM SULFATE | 5.74 G / SACHET |